Tag: clinical trials

The FDA Just Launched Real-Time Clinical Trials. Here Is What That Means, Why It Matters, and What Could Go Wrong.

It takes an average of 10 to 12 years to bring a new drug from discovery to approval in the United States. A significant portion of that time is not active research. It is waiting. Waiting for data from trial sites to reach sponsors. Waiting for sponsors to analyze and compile that data. Waiting for the FDA to receive a package, assign reviewers, and begin their assessment. Then waiting again, between phases, while the next study design is written and the next application is prepared.

FDA Commissioner Marty Makary put a number on it on April 28, 2026: 45 percent of drug development time is dead time. Not failed experiments or necessary science. Just administrative and logistical lag built into a sequential, phase-based system that has operated largely the same way for 60 years.

On that same date, the FDA announced the launch of real-time clinical trials (RTCT), a new model in which the agency receives safety signals and efficacy data from ongoing trials as they are generated, rather than months or years after the fact. Two cancer drug trials are already live under the program. A broader pilot is scheduled for summer 2026. If the approach works at scale, it could be the most significant structural change to drug development in a generation.

The Problem Being Solved: 60 Years of Sequential Waiting

To understand why real-time clinical trials are significant, it helps to understand exactly how the current system works and where the time goes.

In the traditional model, clinical trial data flows in one direction and at structured intervals. Trial sites collect patient data. That data is periodically uploaded to a sponsor’s database. The sponsor’s biostatistics team analyzes the accumulated data. The analysis is compiled into a formal submission. That submission travels to the FDA. Reviewers are assigned. Review begins. If there is a safety signal, it might be weeks or months old by the time the FDA first sees it. If a Phase 1 trial shows promising efficacy, a new Phase 2 protocol must be written and approved before the next patient is enrolled, with a hiatus in between.

The FDA’s own description of the problem is direct: early-phase trials are characterized by high uncertainty, limited patient populations, and inefficient decision-making processes. Data signals that could immediately inform a dose adjustment, an enrollment modification, or a go/no-go decision sit in a pipeline, aging, while administrative processes catch up.

What 45% dead time actually means in practice Commissioner Makary’s statement that 45% of drug development time is dead time refers to the gaps and lags built into the sequential phase structure. This includes the interval between Phase 1 completion and Phase 2 initiation, the time between Phase 2 data lock and NDA submission, and the review clock itself. For a drug with a 10-year development timeline, that is roughly 4.5 years that could theoretically be reduced or eliminated if data moved faster and decisions could be made in real time. Even a 20% reduction would translate to approximately 2 years off the development clock for a single drug. The downstream implication for patients is concrete: if promising therapies reach Phase 3 faster, reach the market faster, or are abandoned faster (freeing resources for the next candidate), the aggregate effect on the drug pipeline is substantial. The question is whether real-time data access changes the speed of regulatory decisions, not just the speed of data transfer.

How Real-Time Clinical Trials Actually Work

The technical infrastructure enabling the RTCT model is built around direct, continuous data connections between trial sites, sponsors, and the FDA, replacing the current batch-submission process with a live data pipeline.

The Paradigm Health SPIRE platform

All trials in the RTCT program use Paradigm Health’s SPIRE platform (Scalable Platform for Integrated Research and Evidence). The platform’s Study Conduct component automates data collection from trial sites and applies AI analysis to identify key safety and efficacy signals. Rather than waiting for the sponsor to run their own analysis and prepare a submission, SPIRE identifies predefined signal thresholds and transmits them to both the sponsor and the FDA as they occur, in days rather than months.

The FDA and each sponsor pre-agree on what constitutes a reportable signal for that specific trial. The criteria are trial-specific and established collaboratively before the trial begins. When the platform detects a signal meeting those criteria, it is transmitted automatically. This means the FDA sees the same data the sponsor sees, at the same time, rather than weeks or months later.

Traditional model versus real-time model

Step	Traditional model	Real-time model
Data collection	Sites collect periodically; upload on schedule	Sites collect continuously; automated upload in near-real time
Signal detection	Sponsor runs periodic analyses; prepares formal report	AI platform detects predefined signals immediately
FDA access	Months to years after data generated	Days after signal detected; same time as sponsor
Safety response	Delayed; based on lagged submissions	Faster; FDA can engage sponsor within days
Phase transition	Hiatus between phases; new protocol required	Potential for continuous development; smoother transitions
Dose decisions	Based on batch data; slow iteration	Near-real-time signal allows faster dose optimization

The Two Live Trials: What Is Being Studied and Why Each Was Chosen

TRAVERSE: AstraZeneca, mantle cell lymphoma

The TRAVERSE trial is a Phase 2, multi-site study being conducted by AstraZeneca in patients with treatment-naive mantle cell lymphoma (MCL), an aggressive B-cell blood cancer. The trial evaluates a combination of three targeted agents: acalabrutinib (Calquence, a BTK inhibitor), venetoclax (Venclexta, a BCL-2 inhibitor), and rituximab (an anti-CD20 monoclonal antibody). Sites include The University of Texas MD Anderson Cancer Center and the University of Pennsylvania.

This trial is already live with real-time data flowing to the FDA. Paradigm Health’s platform has received and validated signals from TRAVERSE, establishing that the technical framework works end-to-end in a real clinical trial environment. This proof-of-concept validation is the most concrete achievement in the April 28 announcement: it is not theoretical anymore.

STREAM-SCLC: Amgen, small cell lung cancer

Amgen’s STREAM-SCLC is a Phase 1b study of tarlatamab (Imdelltra), a bispecific T-cell engager targeting DLL3, in patients with limited-stage small cell lung carcinoma. Tarlatamab already has FDA approval for extensive-stage SCLC; this trial is studying the drug in limited-stage disease, which has a more favorable baseline prognosis. Site selection for STREAM-SCLC is still in process, making it slightly behind TRAVERSE in the pilot timeline.

Amgen Chief Medical Officer Paul Burton described the approach at the FDA press conference: the new model sits alongside traditional randomized study approaches rather than replacing them. The STREAM-SCLC trial’s value in the pilot is demonstrating that real-time data transmission works for a Phase 1b study involving a novel mechanism in a disease where dose optimization and safety monitoring are particularly important.

“For 60 years, we’ve been conducting clinical trials in the same way, where key data signals can take years to reach the FDA. The lag time can delay regulatory decisions unnecessarily and slow down the drug development timeline.” — FDA Commissioner Marty Makary, MD, MPH. April 28, 2026.

The Broader Pilot: Timeline, Scope, and Who Can Participate

Beyond the two live proof-of-concept trials, the FDA published a Request for Information (RFI) in the Federal Register titled “AI-enabled optimization of early-phase clinical trials pilot program.” This invites sponsors, contract research organizations (CROs), and trial sites to propose studies for inclusion in a broader RTCT program.

Milestone	Date or detail
RFI comment deadline	May 29, 2026
Final selection criteria published	July 2026
Pilot selections complete	August 2026
Pilot program launch	Summer 2026
Platform requirement	All participating trials must use Paradigm Health’s SPIRE platform
Priority areas for next cohort	Early-phase oncology, neurology, and rare disease programs
Projected benefit	20 to 40% reduction in overall clinical trial duration

The RFI specifies that the FDA is looking for sponsors with active early-phase programs in oncology, neurology, and rare diseases. These areas share the characteristic of small patient populations, high medical need, and decision points where real-time data access could most meaningfully accelerate go/no-go decisions. The requirement to use Paradigm Health’s platform creates a standardized data architecture across the pilot, which is essential for the FDA to build operational experience with the model.

What This Means for Patients in Clinical Trials and Patients Waiting for New Treatments

Faster safety response

The most immediate patient-facing benefit of real-time data is faster safety monitoring. In the current model, a safety signal that emerges in week 6 of a trial may not reach the FDA until the next data package is submitted, potentially weeks or months later. Under the RTCT model, that same signal reaches the FDA within days. This means the agency can engage with the sponsor, request a dose modification, or recommend a protocol change much faster than the current system allows. For patients currently enrolled in a trial, this is a direct safety benefit.

Faster development timelines

If the projected 20 to 40% reduction in trial duration holds at scale, the average drug development timeline could compress from 10 to 12 years to somewhere closer to 7 to 9 years. For patients with serious or life-threatening conditions, that difference is not abstract. Every year of acceleration means earlier access to treatments that could change outcomes.

Earlier termination of failing trials

Accelerating development is not only about getting promising drugs to market faster. It also means identifying drugs that are not working or are causing unexpected harm and stopping those trials sooner. In the current model, a drug that is failing may consume years of patient enrollment and sponsor resources before the signal becomes clear enough to act on. Real-time data makes that signal visible earlier.

The Legitimate Questions This Initiative Still Needs to Answer

The RTCT initiative is genuinely promising, and the proof-of-concept success with TRAVERSE is a meaningful milestone. It also raises several questions that the field will need to work through as the program expands.

Single-platform dependency. Requiring all pilot participants to use Paradigm Health’s SPIRE platform creates a bottleneck of a different kind. If the program expands to dozens or hundreds of trials, a single-vendor infrastructure carries concentration risk. What happens when the platform experiences downtime? Who audits the AI signal detection algorithms for accuracy? These are operational questions the summer 2026 pilot will need to begin answering.
Data integrity and pre-specified signals. The system works by pre-agreeing on signal definitions before the trial begins. This is scientifically sound but also means the power of real-time data is limited to what sponsors and the FDA anticipated in advance. Unexpected safety signals that do not fit the pre-specified criteria may still be delayed. The governance framework for handling off-protocol signals needs to be explicit.
Regulatory precedent and legal framework. The traditional clinical trial submission process is embedded in decades of regulation, guidance, and legal precedent. Real-time data sharing between sponsors and the FDA raises questions about whether pre-submission access changes the legal standard for what constitutes a formal submission, how disagreements between the FDA’s real-time assessment and the sponsor’s formal analysis are adjudicated, and what happens to expedited review timelines when continuous data is already available.
Equity in access to the program. The requirement to use a specific third-party platform adds cost and technical infrastructure requirements that may favor large pharmaceutical companies over smaller sponsors, academic medical centers, and nonprofits. If the program expands with the same single-platform requirement, it risks becoming a tool that primarily accelerates development for companies with the resources to meet the infrastructure bar.
What “45% dead time” actually includes. Commissioner Makary’s figure is striking, but dead time is not uniformly distributed across drug development. Some of it is genuine administrative lag that faster data pipelines can address. Some of it is necessary scientific deliberation, protocol revision, and peer review that should not be rushed. The 20 to 40% projected time reduction needs to be validated against actual pilot data before it becomes a planning assumption.

Where This Fits in the Broader FDA Modernization Story

The real-time clinical trials initiative did not emerge in isolation. It is part of a pattern of FDA actions in 2025 and 2026 aimed at using artificial intelligence and improved data infrastructure to accelerate drug development without reducing evidence standards. Other pieces of the same picture include the Commissioner’s National Priority Voucher program, which compressed review timelines for priority applications from 10 to 12 months to under 60 days in some cases, and the expansion of the FDA’s AI use in its own review processes.

The RTCT initiative targets a different part of the pipeline than the CNPV program. CNPVs compress the review clock after an NDA is submitted. RTCT aims to compress the development clock before the NDA even exists. Together, they represent a coherent strategy to attack both ends of the 10 to 12 year timeline simultaneously.

What happens next

The May 29, 2026 deadline for RFI comments will be the first public input into how the broader pilot is structured. FDA plans to finalize selection criteria in July and make pilot selections in August. The summer 2026 cohort will be the real test of whether RTCT works at scale across multiple sponsors and disease areas, not just in two carefully chosen proof-of-concept trials.

For patients following drug development in cancer, rare disease, or neurology, the practical upshot is this: if the projected timeline reductions are real, drugs currently in Phase 1 trials could reach Phase 3, or even approval, years sooner than the current system would deliver them. That is a meaningful promise. Whether it holds depends on execution, governance, and the operational questions the next two years of piloting will need to answer. HED will continue tracking the program as the summer 2026 pilot takes shape.

Sources

FDA press announcement: FDA Announces Major Steps to Implement Real-Time Clinical Trials. FDA.gov. April 28, 2026.

HHS announcement: WTAS: FDA Announces Major Steps to Implement Real-Time Clinical Trials. HHS.gov. April 28, 2026.

STAT News (paywalled): FDA testing speedier drug development with real-time clinical trials. STAT News. April 28, 2026. By Lizzy Lawrence.

Fierce Biotech: FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board. fiercebiotech.com. April 28, 2026.

pharmaphorum: Amgen, AZ will pilot FDA’s real-time clinical trial plan. pharmaphorum.com. April 28, 2026.

Nextgov/FCW: FDA to pilot real-time clinical drug trials through cloud and AI. nextgov.com. April 28, 2026.

Clinical Trials Arena: FDA launches pilot for real-time clinical trials. clinicaltrialsarena.com.

HLTH: FDA Launches Real-Time Clinical Trials Pilot with AstraZeneca and Amgen. hlth.com.

Becaris Publishing: FDA sets out plans for real-time clinical trials, aiming to streamline evidence generation. becarispublishing.com.

Paradigm Health SPIRE platform: Paradigm Health. SPIRE: Scalable Platform for Integrated Research and Evidence. paradigmhealth.ai.

WinBuzzer summary with pilot details: FDA Begins Real-Time AI Trial Pilot with AstraZeneca, Amgen. winbuzzer.com. May 2, 2026.

Disclaimer: Health Evidence Digest provides general information about FDA regulatory developments and health policy for educational purposes. This content is not a substitute for professional medical advice. The real-time clinical trials program is in an early pilot stage; outcomes, timelines, and program structure are subject to change as the pilot progresses.

May 15, 2026

Ozempic for PCOS? Clinical Trials Are Testing It Right Now. Here’s What the Research Will Need to Show.

If you have polycystic ovary syndrome and have been following health news over the past year or two, you have almost certainly wondered about semaglutide. The GLP-1 receptor agonist that transformed conversations about obesity and type 2 diabetes is now being formally investigated as a treatment for PCOS. Multiple clinical trials are actively enrolling patients in 2026.

The scientific rationale is genuinely compelling. The existing evidence from smaller studies is encouraging. But there is an important distinction between buzz and evidence, and for a condition as complex and heterogeneous as PCOS, that distinction matters enormously. Semaglutide is not approved for PCOS. No drug is specifically approved for PCOS. The question these trials are trying to answer is whether semaglutide should be.

This post covers the biology behind why semaglutide makes sense for PCOS, what published data already shows, which trials are now running and what they are specifically measuring, and what questions still need answers before this becomes standard practice.

PCOS: Why Treatment Has Always Been a Patchwork

Polycystic ovary syndrome affects an estimated 10% of women of reproductive age worldwide, making it one of the most common endocrine disorders in women. Despite that prevalence, there is no FDA-approved drug specifically for PCOS. Treatment today consists of medications developed for other conditions, repurposed off-label: oral contraceptives for cycle regulation, metformin for insulin resistance, spironolactone for androgen-related symptoms like excess hair growth and acne, and fertility medications for those trying to conceive.

The patchwork approach exists because PCOS is not a single disease. It is a syndrome with multiple overlapping features that present differently from woman to woman. To receive a PCOS diagnosis under the Rotterdam criteria, a woman must have two of the following three: irregular or absent ovulation, elevated androgen levels (causing symptoms like hirsutism, acne, and hair loss), and polycystic-appearing ovaries on ultrasound. Many but not all women with PCOS also have insulin resistance and metabolic features. A significant proportion have obesity. A meaningful minority, sometimes estimated at 20 to 30%, are lean.

What PCOS actually involves: the four main feature clusters Ovulatory dysfunction: Irregular or absent periods, anovulation, and associated difficulty conceiving. This is the most common reason women seek evaluation. Hyperandrogenism: Elevated testosterone and related androgens causing hirsutism (excess body and facial hair), acne, and androgenic hair loss. This is the feature most affecting quality of life for many women. Metabolic features: Insulin resistance (present in 50 to 70% of women with PCOS regardless of weight), dyslipidemia, elevated fasting glucose, and increased risk of type 2 diabetes and cardiovascular disease later in life. Psychological features: Depression, anxiety, and disordered eating occur at significantly higher rates in women with PCOS than in the general population, though these are often underaddressed in standard care.

Why Semaglutide Makes Biological Sense for PCOS

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide 1, a gut hormone that stimulates insulin secretion in response to meals, slows gastric emptying, and signals satiety to the brain. It was developed for type 2 diabetes and obesity, both conditions strongly driven by insulin resistance. This is where the PCOS connection begins.

In PCOS, insulin resistance is not just a complication. It is a central driver and amplifier of the disorder. Elevated insulin levels act directly on the ovary, specifically on theca cells, to stimulate androgen production. More insulin means more testosterone and DHEA-S. More androgens mean disrupted follicle development, impaired ovulation, and worsened symptoms. It also feeds back into insulin resistance through inflammatory and metabolic pathways, creating a self-reinforcing cycle.

Reducing insulin resistance has long been a therapeutic target in PCOS. Metformin, the current first-line metabolic treatment, works primarily by reducing hepatic glucose output and improving insulin sensitivity. GLP-1 receptor agonists reduce insulin resistance through a complementary but distinct pathway: they enhance glucose-stimulated insulin secretion, reduce postprandial glucose spikes, lower fasting insulin, and produce significant weight loss that further improves insulin sensitivity. For many women with PCOS, this combination of effects addresses multiple features of the disorder simultaneously.

For a broader overview of what the 2026 research shows about GLP-1 medications across the full spectrum of fertility, ovulation, and pregnancy safety in PCOS, see our companion post: GLP-1 Medications and PCOS: What the 2026 Research Actually Shows.

What Published Evidence Already Shows

The current evidence base for GLP-1 receptor agonists in PCOS comes from a mix of older liraglutide trials, smaller semaglutide studies, and published meta-analyses that synthesize this literature. It is encouraging. It is also preliminary.

The published meta-analyses

A 2024 meta-analysis published in the Journal of Diabetes and Its Complications pooled data from four randomized controlled trials involving 176 women with PCOS treated with GLP-1 receptor agonists (primarily liraglutide, with some semaglutide). Compared to placebo, GLP-1 agonists produced:

Outcome	Result vs. placebo
Waist circumference	Reduced by 5.16 cm (95% CI 4.21 to 6.11; p less than 0.00001)
BMI	Reduced by 2.42 units (95% CI 1.74 to 3.10; p less than 0.00001)
Serum triglycerides	Reduced significantly (MD −0.20 mmol/L; p less than 0.00001)
Total testosterone	Reduced significantly (MD −1.33 nmol/L; 95% CI −2.55 to −0.12; p=0.03)
HOMA-IR (insulin resistance)	Significant improvement

Source: Morais et al. Journal of Diabetes and Its Complications. 2024;38(10):108834. doi:10.1016/j.jdiacomp.2024.108834

A May 2025 meta-analysis in Scientific Reports, searching databases through October 2024, reached broadly consistent conclusions: GLP-1 receptor agonists outperformed both placebo and metformin on anthropometric and metabolic outcomes in women with PCOS, with additional improvements in androgen markers and lipid profiles.

The liraglutide RCT and the menstrual regularity finding

The most robust individual trial in this space is the Nylander et al. 2017 randomized controlled trial published in Human Reproduction, which enrolled 72 women with PCOS. Participants received liraglutide (the predecessor GLP-1 agonist to semaglutide) for 26 weeks. Results showed significant reductions in BMI, free androgen index, fasting insulin, and LH/FSH ratio compared to placebo. Notably, 44% of women in the liraglutide group achieved regular menstrual cycles by week 24 versus significantly fewer in the placebo group. That menstrual regularity finding is the most clinically meaningful single result from the existing literature.

Combination semaglutide plus metformin

A prospective randomized controlled trial published in 2025 specifically examining overweight and obese women with PCOS assigned participants to metformin alone, semaglutide alone, or combination therapy. The combination group outperformed metformin monotherapy in reducing BMI, androgen levels, insulin resistance, and menstrual irregularities. Notably, the natural pregnancy rate was significantly higher in the combination group than in the metformin-only group. This is the most direct evidence to date supporting a fertility benefit, though the trial was not large enough to draw definitive conclusions and was conducted in a specific patient population.

The honest limitations of the existing evidence base The published meta-analyses and most individual trials have important limitations that must be acknowledged before drawing clinical conclusions. Sample sizes are small: The 2024 meta-analysis pooled just 176 participants across four trials. The 2025 Scientific Reports meta-analysis similarly covered a limited participant pool. These are underpowered to detect meaningful differences in rarer outcomes like live birth rates. Populations are selective: Most trials enrolled women with PCOS and obesity or overweight. The evidence base for women with lean PCOS (BMI under 25 with documented insulin resistance) is far more limited, and some benefits may be primarily mediated through weight loss rather than any direct hormonal effect. Follow-up is short: Most trials run 12 to 28 weeks. The long-term effects of GLP-1 agonist use on reproductive function, ovarian reserve, and metabolic health in young women with PCOS over years of use are not yet characterized. Primary endpoints vary: Different trials measured different outcomes. Without a consistent primary endpoint across studies, synthesizing results into a definitive conclusion is difficult. The ongoing trials are attempting to address this.

The 2025 to 2026 Trials: What They Are Specifically Studying

Several clinical trials registered and recruiting in 2025 and 2026 are specifically investigating semaglutide in women with PCOS. Here are the most relevant currently active programs.

RESTORE trial: NCT05819853 (University of Colorado)

This is the most clinically ambitious of the currently active trials. RESTORE (Role of Semaglutide in Restoring Ovulation in Youth and Adults with Polycystic Ovary Syndrome) is a Phase 3 study enrolling 80 girls and women aged 12 to 35 years old with obesity and PCOS. Participants receive up to 10 months of semaglutide with dose escalation per manufacturer recommendations, with a maximum dose of 1.7 mg.

Feature	Details
NCT number	NCT05819853
Phase	Phase 3
Sponsor	University of Colorado, Denver
Age range	12 to 35 years
Estimated enrollment	80 participants
Treatment	Semaglutide (Wegovy/Ozempic) injectable, 10 months, dose escalation to max 1.7 mg
Primary endpoint	Change in ovulation frequency before and after semaglutide
Secondary endpoints	Change in whole-body insulin sensitivity; change in ovarian morphology; androgen levels; metabolic markers
Projected completion	February 2028
Status	Recruiting

The choice of ovulation frequency as the primary endpoint is significant. Rather than measuring weight loss or metabolic markers as primary outcomes, RESTORE is asking the most clinically meaningful question for a reproductive-age population: does semaglutide restore the normal ovulatory function that PCOS disrupts? The adolescent inclusion (ages 12 to 17) is also notable, as it addresses the understudied question of whether early metabolic intervention in young women with PCOS can improve reproductive outcomes before the condition becomes entrenched.

Semaglutide and PCOS: Emerging Treatment Strategy (NCT06222437)

Sponsored by Methodist Health System, this Phase 1 single-arm interventional study focuses specifically on ovulation and androgen outcomes. Its primary objective is to determine the effect of semaglutide on ovulation and menstrual regularity, and it also measures testosterone, sex hormone-binding globulin (SHBG), and changes in hirsutism. This is one of the few trials that lists androgen-specific clinical measures (not just lab values) as a primary focus, making it directly relevant for women whose main PCOS burden is hirsutism and acne rather than fertility concerns.

Semaglutide vs. metformin in PCOS (NCT05646199, NCT06896981)

Two Phase 2/3 trials are specifically comparing semaglutide against the current standard metabolic therapy for PCOS. The University of Hull trial (NCT05646199) randomizes 60 women with PCOS and obesity to semaglutide or metformin over 28 weeks, with primary endpoint of weight loss and secondary endpoints including free androgen index, glucose tolerance, and blood pressure. The Bangladesh trial (NCT06896981) is evaluating the combination of low-dose semaglutide plus metformin versus metformin alone over 12 weeks in 30 women with PCOS and obesity.

The metformin comparison matters clinically. If semaglutide is going to displace or be added to metformin in PCOS care, it needs to demonstrate it does something meaningfully better than the existing cheap, well-tolerated, off-patent treatment. Head-to-head data is more actionable for prescribers than placebo-controlled data alone.

What the Trials Will Need to Show

For semaglutide to move from promising to proven in PCOS, the clinical trials will need to demonstrate several things that smaller studies have not yet conclusively shown.

Ovulatory restoration across the weight spectrum. Most trial participants have obesity. Whether semaglutide restores ovulation in normal-weight women with PCOS, where the mechanism is less clearly tied to weight loss and more to a possible direct hormonal effect, is not yet established.
Androgen normalization and symptom improvement. Lab values are useful, but what patients care about is whether hirsutism, acne, and hair loss actually improve. Trials need patient-reported outcome measures and validated clinical scales for these symptoms, not just serum testosterone numbers.
Live birth rates for women trying to conceive. This is the endpoint that matters most for a large proportion of the PCOS population. One trial showed higher natural pregnancy rates with combination semaglutide plus metformin, but live birth rate data is absent from most studies. And critically, semaglutide must be stopped before attempting conception, so the fertility benefit question is more nuanced than it first appears.
Long-term safety in reproductive-age women and adolescents. Semaglutide’s safety data comes predominantly from adults with diabetes or obesity, typically older than the PCOS population. The RESTORE trial’s inclusion of participants as young as 12 will generate important adolescent safety data that currently does not exist.
Efficacy in lean PCOS. Roughly 20 to 30% of women with PCOS have a BMI under 25. Their insulin resistance is real but may be less severe, and the weight loss mechanism that drives metabolic improvement in obese participants may contribute less to benefit in this group. None of the current trials are designed specifically for lean PCOS.

The Pregnancy Contraindication: A Critical Practical Issue

Semaglutide is contraindicated during pregnancy. This is not a precautionary label statement. Animal studies have shown fetal harm at doses producing exposures similar to the human therapeutic dose. The FDA prescribing information for both Ozempic and Wegovy includes a recommendation to discontinue semaglutide at least two months before a planned pregnancy, to allow for adequate washout given the drug’s approximately one-week half-life.

For women with PCOS who are actively trying to conceive, this creates a specific clinical scenario that requires careful planning. Semaglutide can be used to improve metabolic parameters and potentially restore ovulatory function, then discontinued before conception is attempted. Effective contraception during treatment is required. The fertility benefit, if it exists, would need to manifest through improved baseline reproductive function that persists after drug discontinuation rather than through ongoing treatment during the conception window.

This is an important conversation to have with a reproductive endocrinologist before starting semaglutide with the goal of improving fertility. The timing, the contraception plan, and the monitoring protocol all require individual clinical guidance. For a full discussion of the safety evidence around GLP-1 medications and pregnancy, including what the 2026 pharmacovigilance data shows, see our post: GLP-1 Medications and PCOS: What the 2026 Research Actually Shows About Fertility, Ovulation, and Pregnancy Safety.

What Women With PCOS Can Do Right Now

If you want to participate in a trial

Search ClinicalTrials.gov using “semaglutide” and “polycystic ovary syndrome” for actively recruiting studies. The RESTORE trial (NCT05819853) at the University of Colorado is enrolling girls and women aged 12 to 35 with obesity and PCOS. Participation in clinical trials is not a last resort. It is how the field generates the evidence that eventually benefits all patients with the condition.

If you are currently managing PCOS

Semaglutide is not currently approved for PCOS, and prescribing it off-label for this indication without a diabetes or obesity co-diagnosis involves clinical judgments that should be made with a specialist, not based on online health content. Evidence-based options available today include metformin for insulin resistance, oral contraceptives or progestins for cycle regulation, spironolactone for androgen symptoms, and letrozole or clomiphene for ovulation induction in those trying to conceive. The 2023 International Evidence-Based PCOS Guideline from Monash University is a reliable reference for understanding the current standard of care.

If you also have obesity or overweight

If your BMI qualifies you for an obesity medication on its own merits (BMI 30 or above, or 27 or above with at least one weight-related comorbidity), semaglutide or another GLP-1 agonist may already be an appropriate treatment for your weight and metabolic health, and there is published evidence suggesting it also benefits PCOS features in this population. This is a conversation worth having with your gynecologist or endocrinologist, who can assess whether you meet criteria for approved obesity pharmacotherapy.

We will be watching these trials closely.

The RESTORE trial at the University of Colorado is the most clinically ambitious study of semaglutide in PCOS currently running, with results expected in 2028. For women with PCOS who have been managing symptoms with off-label therapies for years, the prospect of a drug that addresses the metabolic root of the condition rather than just managing individual symptoms is worth following carefully. The best resources for staying current on PCOS care include ACOG, the Androgen Excess and PCOS Society, and the international evidence-based PCOS guideline from Monash University.

For more women’s health coverage on Health Evidence Digest, see our posts on new 2026 cervical cancer screening guidelines and the first FDA-approved non-hormonal endometriosis drug entering human trials.

Sources

RESTORE trial registration: Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome. NCT05819853. ClinicalTrials.gov.

NCT06222437: Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy. Methodist Health System. ClinicalTrials.gov.

NCT05646199: Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS). University of Hull. ClinicalTrials.gov.

NCT06896981: Semaglutide in Women With Polycystic Ovary Syndrome and Obesity. BSMMU, Bangladesh. ClinicalTrials.gov.

2024 meta-analysis (JDC): Morais BAA et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation. Journal of Diabetes and Its Complications. 2024;38(10):108834. doi:10.1016/j.jdiacomp.2024.108834

2025 meta-analysis (Scientific Reports): Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women. Scientific Reports. May 2025. doi:10.1038/s41598-025-99622-4

GLP-1 RAs in PCOS narrative review: Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS. Endocrine Connections. 2025;14(5). doi:10.1530/EC-24-0529

2024 PCOS guideline meta-analysis: Goldberg et al. Anti-obesity pharmacological agents for PCOS: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obesity Reviews. 2024;25(5):e13704. doi:10.1111/obr.13704

Combination semaglutide + metformin in PCOS: Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with PCOS. PMC12297736. pmc.ncbi.nlm.nih.gov. 2025.

Patient resources: ACOG PCOS FAQ | Androgen Excess and PCOS Society | International PCOS Guideline | ClinicalTrials.gov

Disclaimer: Health Evidence Digest provides general information about clinical research and health topics for educational purposes. This content is not a substitute for professional medical advice. Semaglutide is not FDA-approved for PCOS. Women with PCOS should speak with their gynecologist, reproductive endocrinologist, or healthcare provider about their individual treatment plan.

May 7, 2026

The First Non-Hormonal Endometriosis Drug Just Entered Human Trials and It Works in a Way Nothing Else Does

📌 Read this first: what this milestone is and isn’t On March 23, 2026, the FDA cleared an Investigational New Drug (IND) application for ENDO-205 (EndoCyclic Therapeutics). IND clearance means the FDA has reviewed enough preclinical and manufacturing data to permit human testing to begin. It is not an approval. It is not proof the drug works in humans. The Phase 1 trial is enrolling healthy premenopausal women of reproductive age, not patients with endometriosis. Phase 1 establishes safety and tolerability. Whether ENDO-205 is effective in women who have the disease will be tested in Phase 2, which could be years away. Most drugs that enter Phase 1 do not reach approval. The science behind ENDO-205 is genuinely novel and the preclinical data is promising. It is also early-stage, and the history of women’s health drug development is full of promising early-stage candidates that did not pan out. This post covers both the science and the appropriate context.

If you have endometriosis, you have probably encountered some version of the same conversation more than once. The pain isn’t that bad. Many women have painful periods. Here’s a birth control pill to help with symptoms. If you’re not trying to get pregnant right now, here’s a hormone therapy that will help. And if none of that works, here’s a surgery, with the understanding that the lesions often come back.

Endometriosis affects an estimated 190 million women and girls worldwide, roughly 1 in 10 of reproductive age. It takes an average of 7 to 10 years from symptom onset to diagnosis in many healthcare systems. And despite the scale of the disease and the severity of its impact on quality of life, fertility, and daily function, the pharmacological options have remained essentially unchanged for decades: suppress hormones, manage symptoms, repeat.

On March 23, 2026, the FDA cleared the Investigational New Drug application for ENDO-205, a first-in-class non-hormonal therapeutic developed by EndoCyclic Therapeutics. Human trials are now beginning. The drug uses a mechanism unlike anything currently approved or in late-stage development for this disease: rather than suppressing the hormonal environment that sustains endometriosis lesions, it targets the lesions themselves.

Endometriosis: The Disease That Took 7 to 10 Years to Diagnose

Endometriosis occurs when tissue similar to the endometrium, the uterine lining, grows outside the uterus. The most common sites are the ovaries, fallopian tubes, and pelvic peritoneum, but lesions can also develop on the bladder, bowel, diaphragm, and in rare cases elsewhere in the body. Each menstrual cycle, this misplaced tissue responds to estrogen and progesterone the way endometrial tissue does everywhere: it thickens, breaks down, and bleeds. But the blood and tissue have nowhere to go. The result is chronic inflammation, scar tissue formation, and adhesions that can fuse organs together.

Symptoms vary widely. Severe dysmenorrhea (menstrual pain) is the most common presenting complaint. Many patients also experience chronic pelvic pain throughout the month, painful intercourse (dyspareunia), pain with bowel movements or urination, heavy menstrual bleeding, and fatigue. Infertility affects 30 to 50% of women with endometriosis. For some, the disease is debilitating. For others, lesions are found incidentally during surgery for another reason with minimal symptoms.

The diagnostic delay: 7 to 10 years is not a rounding error The average time from first symptom to confirmed endometriosis diagnosis is 7 to 10 years in most high-income countries, and longer in settings with less gynecological specialist access. This delay is not primarily a technological problem. Endometriosis cannot be diagnosed with a blood test, an ultrasound, or an MRI alone (though imaging can suggest it). The gold standard for definitive diagnosis has historically been laparoscopic surgery with biopsy. The result: for years, clinicians who were not prepared to offer surgery would offer empirical treatment, a birth control pill or other hormonal suppression, without confirming the diagnosis. This masked symptoms without establishing a diagnosis and delayed specialist referral. In March 2026, ACOG updated its clinical guidance to state that a clinical diagnosis based on symptoms and physical examination is now sufficient to begin treatment, and that surgical confirmation is no longer required before care begins. This is a meaningful change in how the disease is managed and it will bring more women into treatment sooner, increasing the clinical pressure to have treatments that work better and carry fewer trade-offs.

The Current Treatment Landscape: Effective, But With Costs

Every pharmacological treatment currently available for endometriosis works by suppressing or modifying the hormonal environment that sustains the disease. The logic is sound: endometrial tissue, including misplaced endometrial-like tissue, responds to estrogen. Reduce estrogen, reduce tissue stimulation, reduce symptoms. But this approach carries the same trade-off at every tier of the treatment ladder.

Treatment class	Examples	How it works	Key limitations
Combined oral contraceptives	Many brands	Suppress ovulation and reduce menstrual flow	~1/3 of patients have progesterone resistance; does not eliminate lesions; contraceptive effect suspends fertility
Progestins	Norethindrone, medroxyprogesterone, dienogest	Suppress endometrial tissue growth	Irregular bleeding, mood changes, bone density loss with long-term use; does not eliminate lesions
GnRH agonists	Leuprolide (Lupron), nafarelin, goserelin	Induce medical menopause by desensitizing pituitary GnRH receptors	Significant hypoestrogen side effects; bone loss; must limit use to 6 to 12 months; fertility suspended; hot flashes
GnRH antagonists (oral)	Elagolix (Orilissa, 2018), relugolix/E2/NETA (Myfembree, 2022)	Directly block GnRH receptors; dose-dependent estrogen suppression; faster return of ovarian function than agonists	Still hormonal suppression; bone density concerns at higher doses; add-back therapy adds complexity; fertility not immediately restored at suppressive doses
Surgery (laparoscopic excision)	Excision or ablation of lesions	Physically removes or destroys lesions	Recurrence rates 20 to 40%+ at 2 years; does not address the underlying biology; repeat surgery has cumulative risks; diagnostic laparoscopy no longer required before treatment

The GnRH antagonist approvals, elagolix in 2018 and the relugolix combination (relugolix/estradiol/norethindrone acetate, Myfembree) in 2022, represented genuine improvements over older GnRH agonists. They are oral, not injectable. They don’t cause an initial symptom flare as agonists do. They allow more granular estrogen control and faster return of ovarian function after stopping. But they are still fundamentally hormonal therapies. They still suppress estrogen. They still suspend fertility at suppressive doses. They still don’t eliminate lesions; they manage symptoms by starving the tissue of hormonal stimulation.

The consequence is a treatment gap that has never been filled: women who cannot tolerate hormonal therapies, women who want to preserve fertility while treating their disease, and women whose symptoms are not adequately controlled by any available option. This is the population ENDO-205 is attempting to reach.

What ENDO-205 Is and How It Works

ENDO-205 is built on EndoCyclic Therapeutics’ proprietary precision peptide platform. The company has spent over a decade developing what it describes as cell-permeating, pH-sensitive peptides, small engineered protein chains designed to act only in diseased tissue.

The pH-sensitivity mechanism: why diseased tissue is different

Healthy human tissue maintains a tightly regulated pH. Diseased tissue, including chronic inflammation sites, tumor microenvironments, and endometriosis lesions, tends to be more acidic. This difference is not incidental; it is a product of the inflammatory and metabolic activity occurring at the site of disease.

EndoCyclic’s peptides are engineered to respond to this pH difference. In the neutral pH environment of healthy tissue, the peptide is largely inert or unable to penetrate cells. In the acidic environment of diseased tissue, the peptide undergoes a conformational change that allows it to penetrate cells and engage its target. This selectivity is the foundational property of the platform: the drug acts where the disease is, and not where it isn’t.

What ENDO-205 targets inside the lesion

The specific intracellular target of ENDO-205 has not been fully disclosed publicly by EndoCyclic. The company has described the program as engaging targets once beyond the limits of traditional therapy, language consistent with transcription factors or signaling regulators (such as components of the Wnt/β-catenin pathway, which has been implicated in endometriosis lesion survival and immune evasion) that do not have accessible pockets for conventional small molecule drugs.

The biological rationale behind the approach relates to a fundamental feature of endometriosis: lesions survive where they shouldn’t. The body normally deploys immune surveillance mechanisms to identify and clear aberrant tissue. In endometriosis, this process fails; lesions evade immune clearance and persist in the peritoneal cavity. ENDO-205 is designed to help the body recognize and eliminate these lesions, targeting the intracellular machinery that allows them to survive the immune environment rather than suppressing the hormone environment that feeds them.

Preclinical data: what it showed, and why it doesn’t prove human efficacy In preclinical animal model studies, ENDO-205 demonstrated elimination of endometriosis lesions and reduction of associated inflammation. No safety signals were observed in GLP (Good Laboratory Practice) toxicology studies, the rigorous preclinical standard required before the FDA will allow human trials to begin. The NIH NICHD granted the program multiple research grants and a commercialization readiness pilot grant with a perfect impact score of 10. This is a genuinely strong preclinical foundation. It is not, however, proof that ENDO-205 works in humans. The translation from animal models to human efficacy in endometriosis has historically been difficult: the peritoneal microenvironment, the immune landscape, and the heterogeneity of lesion types in women differ meaningfully from rodent models. Many drugs that cleared endometriosis lesions in animals have not done so in humans. The Phase 1 trial, which enrolls healthy women (not patients with endometriosis) to establish safety and tolerability, will not answer the efficacy question. Phase 2 trials in women with the disease, still years away, will be the first test of whether the mechanism translates.

The Fertility Question: Why Non-Hormonal Treatment Matters So Much

Thirty to fifty percent of women with endometriosis experience infertility. The disease affects fertility through multiple mechanisms: scarring and adhesions that distort pelvic anatomy, damage to ovarian reserve from endometriomas, inflammatory changes in the peritoneal environment that impair egg quality and sperm function, and in some cases, the hormonal suppression of treatments used to manage the disease.

Every hormonal treatment for endometriosis suspends fertility while the patient is taking it. GnRH agonists and antagonists at suppressive doses prevent ovulation. Combined oral contraceptives prevent pregnancy. Progestins alone can disrupt ovulation at higher doses. This means women with endometriosis who want to conceive face an impossible choice under the current treatment paradigm: treat the disease or preserve the possibility of pregnancy. Cyclic treatment with rest periods for conception attempts is the imperfect current standard.

A non-hormonal therapy that works at the lesion level, without touching the hormonal environment, would theoretically allow treatment to continue without suspending ovulation. Whether ENDO-205 achieves this in practice depends entirely on the clinical data, which has not yet been generated. But the theoretical property of a non-hormonal approach is precisely why it is generating interest among reproductive endocrinologists alongside gynecologists.

For women with overlapping PCOS, the same fertility preservation question is arising with GLP-1 agonist trials. Read more about that here.

What an IND Clearance Actually Means and What It Doesn’t

For patients following this news, it’s worth being specific about what FDA IND clearance does and doesn’t represent.

What IND clearance means	What IND clearance doesn’t mean
The FDA reviewed the preclinical safety package and manufacturing data	The FDA has approved the drug or endorsed its efficacy
The company may now conduct human clinical trials in the U.S.	The drug is available to patients
Preclinical GLP toxicology studies showed no safety signals in animals	The drug is safe or effective in humans
The scientific foundation is strong enough to test in humans	The drug will eventually be approved
Phase 1 can now begin (safety testing in healthy volunteers)	Phase 1 will produce efficacy data in patients with endometriosis

The clinical development pathway from IND to potential approval is long. Phase 1 (safety, typically 1 to 2 years), Phase 2 (efficacy in patients with endometriosis, typically 2 to 4 years), Phase 3 (pivotal efficacy and safety, typically 3 to 5 years), and NDA review. The entire process, if successful at every stage, takes roughly 8 to 10 years from IND clearance. Most drugs do not make it through every stage. The overall success rate from Phase 1 to approval across all drug types is approximately 12 to 14%; for drugs targeting complex diseases in women’s reproductive health, the history is sobering.

This context is not intended to diminish the scientific significance of what EndoCyclic has achieved. A decade of platform development, multiple NIH grants, GLP toxicology clearance, and FDA IND acceptance represent real scientific rigor. The point is that the path from promising preclinical candidate to approved drug in the clinic is long, uncertain, and requires results at each stage before it can proceed.

The Broader Endometriosis Pipeline: What Else Is Coming

ENDO-205 is not the only non-standard approach being explored in the endometriosis space. The growing recognition of the disease’s burden has attracted more research attention over the past five years than the previous thirty combined. Other approaches in clinical development include:

HMI-115 (Hope Medicine): A monoclonal antibody targeting the prolactin receptor. A Phase 2 trial reported positive results in 2025, showing meaningful pain reduction. This is the most clinically advanced non-GnRH-antagonist approach in the pipeline. Search ClinicalTrials.gov for current enrollment status.
Anti-inflammatory and immune modulatory approaches: Several programs are targeting the peritoneal inflammatory environment rather than the hormonal environment, including anti-cytokine strategies. None has yet reached Phase 3.
Angiogenesis inhibitors: Endometriosis lesions require new blood vessel formation to establish and grow. Targeting this process is a biologically sound approach being explored in early-stage trials.
FemLUNA (EndoCyclic Therapeutics): ENDO-205’s companion program, a non-invasive imaging agent designed to accurately detect endometriosis lesions, including superficial ones that are often missed by ultrasound and MRI. Accurate non-invasive diagnosis would address one of the core drivers of the 7 to 10 year diagnostic delay.

The convergence of the ACOG diagnostic guidance change, the entry of novel mechanisms into clinical trials, and the growing research attention to the disease represents a genuine inflection point for endometriosis care, even if none of these programs will reach patients for years.

What Patients Can Do Right Now

ENDO-205 is not available to patients. The Phase 1 trial recruits healthy premenopausal women, not people with endometriosis. Here is what is actionable today for people living with the disease:

Seek specialist care. The updated ACOG guidance means you do not need surgical confirmation to receive treatment. A clinical diagnosis based on symptoms and examination is now sufficient to begin. If your symptoms are being dismissed or undertreated, a referral to a gynecologist or reproductive endocrinologist with endometriosis expertise is the most impactful step.
Explore what’s currently approved. Elagolix (Orilissa) and the relugolix combination (Myfembree) are both approved for moderate-to-severe endometriosis pain and are newer, better-tolerated alternatives to older GnRH agonist injections. If you’ve only been offered OCP or are experiencing inadequate pain control, ask your provider about these options.
Connect with advocacy organizations. The Endometriosis Association, Endometriosis Foundation of America, and the Nancy’s Nook Endometriosis Education community maintain updated information on disease management and specialist directories.
Track the clinical trial landscape. If Phase 2 trials of ENDO-205 open for enrollment in patients with endometriosis in coming years, they will be listed at ClinicalTrials.gov. Searching “endometriosis non-hormonal” or “ENDO-205” there is how to monitor for enrollment opportunities.

The entry of ENDO-205 into human trials is meaningful precisely because it represents a fundamentally different idea about how endometriosis might be treated. Whether that idea survives contact with human biology is still to be determined, and it will take years to find out. In the meantime, the most important thing for people living with this disease is not waiting for future options. The Endometriosis Foundation of America, Nancy’s Nook on Facebook (a clinician-moderated group), and ACOG’s patient resource page are the strongest starting points for current, evidence-based guidance on diagnosis and treatment. We will continue tracking ENDO-205’s clinical progress.

For related coverage of changing evidence in women’s health care, see our posts on new 2026 cervical cancer screening guidelines and GLP-1 medications and PCOS fertility research in 2026.

Sources

EndoCyclic press release: EndoCyclic Therapeutics Announces FDA Clearance of IND Application for ENDO-205. PR Newswire. March 23, 2026.

Contemporary OB/GYN: FDA clears ENDO-205 Investigational New Drug application for endometriosis. contemporaryobgyn.net. March 23, 2026.

Future Fem Health: EndoCyclic Therapeutics advances non-hormonal endometriosis drug into clinical trials. futurefemhealth.com. March 23, 2026.

EndoCyclic website: EndoCyclic Therapeutics platform description and program overview.

GnRH antagonist landscape: Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis. PMC12239828. pmc.ncbi.nlm.nih.gov. 2025.

Elagolix/relugolix systematic review: Efficacy of Elagolix and Relugolix for Treatment of Pelvic Pain in Endometriosis. PMC12515486. pmc.ncbi.nlm.nih.gov. 2025.

Pipeline overview: The future of endometriosis research: biotech breakthroughs to watch in 2025. Labiotech.eu. November 2025.

ACOG diagnostic guidance: Updated clinical guidance: clinical diagnosis based on symptoms now sufficient to begin treatment. ACOG. March 2026.

WHO endometriosis fact sheet: Endometriosis. World Health Organization.

Patient resources: Endometriosis Foundation of America | Endometriosis Association | ACOG patient resources | ClinicalTrials.gov

Disclaimer: Health Evidence Digest provides general information about clinical drug development and health research for educational purposes. ENDO-205 is an investigational drug not approved by the FDA. This content is not a substitute for professional medical advice. If you are living with endometriosis or suspected endometriosis, please consult a qualified gynecologist or reproductive endocrinologist about treatment options currently available to you.

May 6, 2026